grade
pharmaceutical primary standard
API family
allopurinol
manufacturer/tradename
EDQM
mp
>300 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
O=C1NC=Nc2[nH]ncc12
InChI
1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
InChI key
OFCNXPDARWKPPY-UHFFFAOYSA-N
Gene Information
human ... XDH(7498)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. For further information and support, including product information leaflets, please go to the website of the issuing Pharmacopoeia.
Application
Allopurinol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Inhibitor of xanthine oxidase and de novo pyrimidine biosynthesis. A classical agent in treatment of hyperuricemia and gout.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Skin Sens. 1
저장 등급
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Sarah Leighton et al.
Experimental dermatology, 22(3), 189-194 (2013-02-08)
Exposure to solar ultraviolet (UV) radiation suppresses adaptive immune responses. This contributes to skin carcinogenesis but may protect from some autoimmune diseases. However, the molecular changes occurring within UV-exposed skin that precipitate the downstream events leading to immune suppression are
Gisele Zandman-Goddard et al.
Rheumatology (Oxford, England), 52(6), 1126-1131 (2013-02-09)
To assess the adherence and persistence with allopurinol therapy among gout patients and to identify risk factors for therapy discontinuation. The study population included adults in Maccabi Healthcare Services, a 2-million member health maintenance organization in Israel, who were diagnosed
Essack Mitha et al.
Rheumatology (Oxford, England), 52(7), 1285-1292 (2013-03-15)
To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial. Hyperuricaemic adults (n = 248) from South